Roxana O Carare Selected Research

Cerebral Amyloid Angiopathy (Congophilic Angiopathy)

11/2021	Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study.
10/2021	The α-dystrobrevins play a key role in maintaining the structure and function of the extracellular matrix-significance for protein elimination failure arteriopathies.
1/2021	Loss of cholinergic innervation differentially affects eNOS-mediated blood flow, drainage of Aβ and cerebral amyloid angiopathy in the cortex and hippocampus of adult mice.
9/2020	Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer's Disease.
1/2019	Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain.
11/2018	The association between hypertensive arteriopathy and cerebral amyloid angiopathy in spontaneously hypertensive stroke-prone rats.
1/2017	Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways.
1/2016	Quantification of molecular interactions between ApoE, amyloid-beta (Aβ) and laminin: Relevance to accumulation of Aβ in Alzheimer's disease.
1/2016	Deposition of amyloid β in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy.
3/2015	Prenatal high-fat diet alters the cerebrovasculature and clearance of β-amyloid in adult offspring.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roxana O Carare Research Topics

Disease

33	Alzheimer Disease (Alzheimer's Disease) 03/2022 - 04/2008
21	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 11/2021 - 04/2008
8	Dementia (Dementias) 01/2022 - 01/2014
6	Cognitive Dysfunction 01/2021 - 01/2009
3	Inflammation (Inflammations) 11/2021 - 10/2012
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 01/2017
3	Cerebral Small Vessel Diseases 11/2018 - 01/2014
3	Stroke (Strokes) 11/2018 - 01/2014
2	Multiple System Atrophy 01/2022 - 11/2020
2	Synucleinopathies 01/2022 - 11/2020
2	Parkinson Disease (Parkinson's Disease) 01/2022 - 11/2020
2	Multiple Sclerosis 11/2021 - 01/2009
2	Hypercapnia 01/2020 - 08/2014
2	Amyloidosis 01/2017 - 08/2014
1	Edema (Dropsy) 01/2022
1	Meningoencephalitis 01/2021
1	Carotid Stenosis (Carotid Artery Stenosis) 01/2021
1	Disease Progression 11/2020
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020
1	Brain Injuries (Brain Injury) 01/2020
1	Macular Degeneration (Age-Related Maculopathy) 12/2019
1	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 10/2019
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2018
1	Maternal Obesity 03/2015
1	CADASIL 01/2015
1	Leukoencephalopathies 01/2015
1	Arteriosclerosis 07/2014
1	Hypertension (High Blood Pressure) 02/2014
1	Hypertensive Nephropathy 01/2014
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2009
1	Virus Diseases (Viral Diseases) 01/2009

Drug/Important Bio-Agent (IBA)

28	Amyloid (Amyloid Fibrils)IBA 03/2022 - 01/2009
8	Amyloid beta-PeptidesIBA 03/2022 - 04/2008
7	Proteins (Proteins, Gene)FDA Link 10/2021 - 07/2014
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 03/2016
5	Peptides (Polypeptides)IBA 01/2017 - 01/2009
3	alpha-SynucleinIBA 01/2022 - 11/2020
3	ApolipoproteinsIBA 01/2016 - 01/2015
2	VaccinesIBA 01/2021 - 11/2020
2	SynucleinsIBA 11/2020 - 01/2020
2	Laminin (Merosin)IBA 01/2020 - 01/2016
2	Fibronectins (Fibronectin)IBA 01/2020 - 03/2015
2	Pharmaceutical PreparationsIBA 05/2016 - 08/2014
2	Apolipoprotein E4IBA 01/2016 - 07/2014
2	Cilostazol (Pletal)FDA LinkGeneric 01/2016 - 08/2014
2	Apolipoproteins E (ApoE)IBA 01/2016 - 01/2015
1	gantenerumabIBA 01/2022
1	GadoliniumIBA 11/2021
1	dystrobrevinIBA 10/2021
1	Cholinergic Agents (Cholinergics)IBA 01/2021
1	AntibodiesIBA 11/2020
1	Adrenergic Receptors (Adrenergic Receptor)IBA 09/2020
1	Tissue Inhibitor of Metalloproteinase-3IBA 12/2019
1	Antisense OligonucleotidesIBA 10/2019
1	Presenilin-1IBA 01/2017
1	Protein Isoforms (Isoforms)IBA 01/2016
1	Protein AggregatesIBA 08/2015
1	CollagenIBA 03/2015
1	Biological ProductsIBA 01/2015
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 08/2014
1	Acetylcholine (Acetylcholine Chloride)FDA Link 08/2014
1	MK-886IBA 01/2014
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2014
1	Fc Receptors (Fc Receptor)IBA 10/2012
1	Antigen-Antibody Complex (Immune Complex)IBA 10/2012
1	AntigensIBA 01/2009

Therapy/Procedure

7	Immunotherapy 01/2022 - 10/2009
6	Therapeutics 01/2022 - 07/2014
1	Intravenous Injections 11/2021
1	Aftercare (After-Treatment) 11/2021